UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia

Blood, 2011-05, Vol.117 (21), p.5723-5732

2011

Volltextzugriff (PDF)

Assessment of transient ischemic dilation (TID) ratio in gated SPECT myocardial perfusion imaging (MPI) using regadenoson, a new agent for pharmacologic stress testing

Journal of nuclear cardiology, 2012-08, Vol.19 (4), p.727-734

2012

Volltextzugriff (PDF)

European aquifer typology: a practical framework for an overview of major groundwater composition at European scale

Environmental earth sciences, 2008-07, Vol.55 (1), p.77-85

2008

Volltextzugriff (PDF)

Stability of measurement of the immature platelet fraction

American journal of hematology, 2010-08, Vol.85 (8), p.622-624

2010

Volltextzugriff (PDF)

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

European journal of cancer (1990), 2015-09, Vol.51, p.S721-S721

2015

Volltextzugriff (PDF)

Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)

Annals of oncology, 2019-10, Vol.30, p.v611-v612

2019

Volltextzugriff (PDF)

1492P - Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)

Annals of oncology, 2019-10, Vol.30, p.v611-v612

2019

Volltextzugriff (PDF)

1492PAssessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1493PLong-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): Post hoc analyses from JAVELIN solid tumour

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1493P - Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): Post hoc analyses from JAVELIN solid tumour

Annals of oncology, 2019-10, Vol.30, p.v612-v613

2019

Volltextzugriff (PDF)

Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): Post hoc analyses from JAVELIN solid tumour

Annals of oncology, 2019-10, Vol.30, p.v612-v613

2019

Volltextzugriff (PDF)

A phase 1/1b, first-in-human, multi-part study of DF6215, an engineered IL-2Rα-active agonist, to investigate the safety, tolerability, pharmacokinetics, and biological and clinical activity in patients with advanced solid tumors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.TPS2704-TPS2704

2024

Volltextzugriff (PDF)

OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S331-S332

2018

Volltextzugriff (PDF)

A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS3163-TPS3163

2023

Volltextzugriff (PDF)

Digital pathology to evaluate PD-L1 IHC scoring as a predictor of outcome with second-line avelumab treatment in patients with non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21539-e21539

2020

Volltextzugriff (PDF)

Avelumab (anti–PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9090-9090

2018

Volltextzugriff (PDF)

A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS7573-TPS7573

2016

Volltextzugriff (PDF)

Radioulnar Synostosis-Hematology (RUS-H) Syndrome: Description of the New Syndrome and Comparison to Similar Syndromes

Blood, 2012-11, Vol.120 (21), p.1100-1100

2012

Volltextzugriff (PDF)

WFD and hydrogeological setting plans: the example of the Tevere River Basin

Environmental science & policy, 2005-01, Vol.8 (3), p.233-237

2005

Volltextzugriff (PDF)

Cardiac manifestations of Wegener's granulomatosis: Case report and review of the literature

Journal of cardiology cases, 2010-10, Vol.2 (2), p.e99-e102

2010

Volltextzugriff (PDF)

Radioulnar Synostosis and Its Hematology and Genetic Associations

Blood, 2010-11, Vol.116 (21), p.2521-2521

2010

Volltextzugriff (PDF)

A Phase III study at high risk for recurrence

Journal for immunotherapy of cancer, 2015-11, Vol.3 (Suppl 2)

2015

Volltextzugriff (PDF)

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

Journal for immunotherapy of cancer, 2015-11, Vol.3 (Suppl 2), p.P166-P166, Article P166

2015

Volltextzugriff (PDF)

Comparison of Outcomes Using Sirolimus -Eluting Stenting in Diabetic Versus Nondiabetic Patients With Comparison of Insulin Versus Non–Insulin Therapy in the Diabetic Patients

The American journal of cardiology, 2007-10, Vol.100 (8), p.1187-1191

2007

Volltextzugriff (PDF)

1 – 25 von 114

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(96)
Mit Volltextzugriff
(95)

Publikationsform

Sprache

Englisch
(114)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Science & Technology
(61)
Life Sciences & Biomedicine
(31)
Physical Sciences
(23)
Chemistry
(19)
Chemistry, Inorganic & Nuclear
(16)
Humans
(16)
Exact Sciences And Technology
(14)
Technology
(13)
Female
(11)
Animals
(9)
Male
(9)
Mössbauer
(9)
Ge, Sn, Pb Derivatives
(8)
Organic Chemistry
(8)
Organometalloidal And Organometallic Compounds
(8)
Organotin
(8)
Organo‐tin Compounds
(8)
Preparations And Properties
(8)
Aged
(7)
Biological And Medical Sciences
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia

Assessment of transient ischemic dilation (TID) ratio in gated SPECT myocardial perfusion imaging (MPI) using regadenoson, a new agent for pharmacologic stress testing

European aquifer typology: a practical framework for an overview of major groundwater composition at European scale

Stability of measurement of the immature platelet fraction

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)

1492P - Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)

1492PAssessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)

1493PLong-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): Post hoc analyses from JAVELIN solid tumour

1493P - Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): Post hoc analyses from JAVELIN solid tumour

Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): Post hoc analyses from JAVELIN solid tumour

A phase 1/1b, first-in-human, multi-part study of DF6215, an engineered IL-2Rα-active agonist, to investigate the safety, tolerability, pharmacokinetics, and biological and clinical activity in patients with advanced solid tumors

OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors

Digital pathology to evaluate PD-L1 IHC scoring as a predictor of outcome with second-line avelumab treatment in patients with non-small cell lung cancer (NSCLC)

Avelumab (anti–PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial

A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D

Radioulnar Synostosis-Hematology (RUS-H) Syndrome: Description of the New Syndrome and Comparison to Similar Syndromes

WFD and hydrogeological setting plans: the example of the Tevere River Basin

Cardiac manifestations of Wegener's granulomatosis: Case report and review of the literature

Radioulnar Synostosis and Its Hematology and Genetic Associations

A Phase III study at high risk for recurrence

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

Comparison of Outcomes Using Sirolimus -Eluting Stenting in Diabetic Versus Nondiabetic Patients With Comparison of Insulin Versus Non–Insulin Therapy in the Diabetic Patients

Suchergebnisse filtern